Amar Desai

Stem cells and drug development, Case Comprehensive Cancer Center @cwru.

[Amar Desai @desailabcwru]

Bittersweet saying goodbye to our graduating seniors Filip, Ria, and Mia. But very excited to watch as they go out and change the world!

[Amar Desai @desailabcwru]

A very happy (belated) Holi from the Desais!

[CWRU School of Medicine @CWRUSOM]

A paper titled published in the @PNASNews from the laboratories of @CWRUSOM professors Andrew Pieper and Sanford Markowitz was awarded the 2025 PNAS Cozzarelli Prize in Biomedical Sciences.

Learn more: https://t.co/w4WCZTMwrN

[Case Western Reserve @cwru]

Case Western Reserve University has been named one of the world’s top universities, ranking 25th globally in @TIME's inaugural World’s Best Universities list! https://t.co/CDDW2N87ov

[Jason Shepherd @JasonSynaptic]

My @NIH study section will not meet tomorrow because of the government shutdown. This may seem trivial but rescheduling these meetings will delay funding decisions for months to even a year! Let alone the uncertainty of what the FY26 budget will be. Awful for US scientists! 😓

[Amar Desai @desailabcwru]

Excited to share our lab’s new review in @StemCellsJournl! Led by @science_klein with Ritisha Rashmil and Angella Blake, we cover how niche modeling, small molecules, and gene-editing advances are helping generate functional HSCs for therapy. https://t.co/PFgUevPFBa

[Amar Desai @desailabcwru]

Excited to be in beautiful San Juan for the Department of Energy @ENERGY “1-2-3 to Cesium Free” workshop. Great talks on alternatives to cesium radiation sources in biomedical research- very relevant to our work @caseccc. Looking forward to continued engagement with this group!

[Amar Desai @desailabcwru]

Thankful to the @ISAC_KUH! These funds have opened up new avenues of research in our lab as we explore how histamine signaling impacts hematopoietic function during aging.

[Innovative Science Accelerator Program @ISAC_KUH]

Since its launch, ISAC has funded over 35 innovative ideas in kidney, urology & hematology research. 💡Now, we're spotlighting the innovators behind them.

Stay tuned for updates from the front lines of discovery.

Dr. Amar Desai
@desailabcwru

#ISACWins #ResearchImpact #STEM

[Case Comp Cancer Ctr @caseccc]

We had a full house today as we welcomed @BDBiosciences to launch our brand new FACSDiscover A8 Cell Analyzer! We’re proud to be one of the first institutions in the Midwest to bring this technology in-house and can’t wait to see the discoveries it helps unlock.

[Amar Desai @desailabcwru]

New work from our lab out this week in @StemCellsJournl! We show that small-molecule inhibition of 15-PGDH improves HSC function and boosts engraftment in aged recipients post transplant.

Proud of the team @caseccc and excited to keep pushing forward.

https://t.co/jMLkahYcZO

[ABME @ABMEjournal]

Breathing shouldn’t be a battle, but for those with idiopathic pulmonary fibrosis (IPF), it often is.

To improve the lives of patients living with this progressive, deadly lung disease, researchers explored a new way to deliver two leading IPF medications – Nintedanib (NTB) and Pirfenidone (PFD) – with fewer side effects and less frequent dosing. By embedding these drugs in microparticles made from beta-cyclodextrin polymers, the team achieved:

🔹 Sustained drug release that maintained therapeutic levels of NTB for over 70 hours
🔹 Significant reductions in inflammation linked to fibrotic lung injury
🔹 Fewer required doses compared to daily NTB regimens

This novel delivery system could make a hard-to-treat disease just a little easier to live with.

𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://t.co/17vcdWL0Jb

𝗦𝘁𝘂𝗱𝘆: Sustained Release of Antifibrotic Nintedanib from Polymer Microparticles Reduces Dosing Frequency While Reducing Inflammation in Preclinical Models of Idiopathic Pulmonary Fibrosis

𝗔𝘂𝘁𝗵𝗼𝗿𝘀: Emmanuel Einyat Opolot, Filip Goshevski, Rahul Chaudhary, Jessica A. Kilgore, Noelle S. Williams, Horst A. von Recum, and @desailabcwru

@cwru
@CaseEngineer
@CWRUSOM
@CWRUBME
@UTSWMedCenter

𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗺𝗮𝗻𝘂𝘀𝗰𝗿𝗶𝗽𝘁: https://t.co/Gyz8DNneUg

[Amar Desai @desailabcwru]

6/ We’re excited to keep building on this to make existing IPF therapies more effective, more tolerable, and easier to use. Check it out here!

https://t.co/WJQvUcaO1q

[Amar Desai @desailabcwru]

1/Excited to share a new team science publication from our lab @caseccc in collaboration with @HA_vonRecum in @CWRUbme.

A quick thread outlining our studies...

[Amar Desai @desailabcwru]

5/ Using a β-cyclodextrin microparticle platform, we developed a slow-release formulation of nintedanib to reduce dosing frequency. The formulation:

▸ Showed sustained release in vitro
▸ Was well-tolerated in mice
▸ 2 low-dose injections ≈ 14 days of high-dose drug

[Amar Desai @desailabcwru]

@Isabel_M_Bravo Awful- so sad to hear this. You should still be proud!

[Amar Desai @desailabcwru]

Bittersweet saying goodbye to Rahul Chaudhary. From an overly earnest undergrad, to seasoned research technician, to medical school in the fall! Very proud of him, and grateful for his time in our lab. @caseccc

[Amar Desai @desailabcwru]

@costinebartell @NIH I’m so sorry! Side note- we started studying impacts of TBI on hematopoiesis and HSC function, we should chat!

[Amar Desai @desailabcwru]

Just found out the study section scheduled to review my grant today was canceled. I spent three months writing it, representing five years of work from my lab. Gutted. @NIH